WARNINGS AND PRECAUTIONS

Severe Skin and Hypersensitivity Reactions

Severe, potentially life-threatening, and fatal skin reactions have been reported. These include cases of Stevens- Johnson syndrome, toxic epidermal necrolysis and erythema multiforme. Hypersensitivity reactions including Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have also been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction...

ADVERSE REACTIONS

Clinical Trial Experience: Adults

The incidence of rash was higher in women compared to men in the Intelence arm in the Phase 3 trials (rash ≥ Grade 2 was reported in 9/60 [15.0%] women versus 51/539 [9.5%] men; discontinuations due to rash were reported in 3/60 [5.0%] women versus 10/539 [1.9%] men).

Clinical Trials Experience: Pediatric Subjects (6 years to less than 18 years of age)

Rash was reported more frequently in female subjects than in male subjects (rash ≥ Grade 2 was reported in 13/64 [20.3%] females versus 2/37 [5.4%] males); discontinuations due to rash were reported in 4% of subjects (4/64 [6.3%] females versus 0/37 [0%] males). Rash (greater than or equal to Grade 2) occurred in 15% of pediatric subjects. In the majority of cases

Postmarketing Experience

Immune System Disorders: Severe hypersensitivity reactions including DRESS and cases of hepatic failure have been reported.

DRUG INTERACTIONS

Table 5 and Table 6 with information regarding coadministration of etravirine with artemether/lumefantrine or telaprevir.

Antimalarials: artemether/lumefantrine – No change in etravirine exposures. Decrease in artemether, dihydroartemisinin and lumefantrine exposures. Caution is warranted when co-administering Intelence and artemether/lumefantrine as it is unknown whether the decrease in exposure of artemether or its active metabolite, dihydroartemisinin, could result in decreased antimalarial efficacy. No dose adjustment is needed for Intelence.

Hepatitis C Virus (HCV) Direct-Acting Antivirals:telaprevir – No change in etravirine exposures. Decrease in telaprevir exposures. There are insufficient data to make a dosing recommendation for telaprevir when used with Intelence.